Imprimis Pharmaceuticals announced that it has made available a compounded formulation of pyrimethamine and leucovorin as a lower-cost alternative to Daraprim (pyrimethamine; Turing Pharmaceuticals).
In August 2015, Turing Pharmaceuticals obtained the exclusive rights to market Daraprim in the United States and increased the price from $13.50 per tablet to a reported $750 per tablet. Imprimis is now offering a customizable compounded formulation of pyrimethamine and leucovorin in oral capsules starting at $99.00 for a 100-count bottle.
Mark L. Baum, CEO of Imprimis, stated that the company will work with clinicians, patients, third-party insurers, pharmacy benefit managers, and buying groups on patient-specific customizable compounded drug formulations at accessible prices.
Daraprim is a folic acid antagonist indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide; acute malaria in combination with other antimalarials only; and chemoprophylaxis of malaria due to susceptible strains of plasmodia.
For more information visit ImprimisPharma.com.